What is ArcticZymes Technologies ASA's (AZT.OL) StockRank?

MoatMap's StockRank for ArcticZymes Technologies ASA (AZT.OL) is 45/100, with a Hold signal. This is a composite score combining Quality (66), Value (20), and Momentum (50) factor ranks across MoatMap's 20,000+ stock universe.

Does ArcticZymes Technologies ASA have an economic moat?

ArcticZymes Technologies ASA (AZT.OL) has a Quality factor score of 66/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is ArcticZymes Technologies ASA a buy, hold, or sell?

MoatMap's current signal for ArcticZymes Technologies ASA (AZT.OL) is Hold, based on a StockRank of 45/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is ArcticZymes Technologies ASA in?

ArcticZymes Technologies ASA (AZT.OL) operates in the Healthcare sector, specifically the Biotechnology industry (Norway).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

AZT.OL

HOLDFLAG

ArcticZymes Technologies ASA · Healthcare · Norway · $107M · Avg Vol: $90K/d

StockRank

P/E (TTM)

78.5x

ROE

4.1%

D/E

0.1x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

A high-quality Norwegian enzyme producer with strong ROIC potential, serving as a critical upstream supplier to molecular diagnostics and biopharma CDMOs. The asset-light model and high switching costs create a strong moat, though valuation remains demanding.

COMPANY DESCRIPTION

ArcticZymes Technologies ASA develops, manufactures, and commercializes novel recombinant enzymes derived from cold-water marine organisms for use in molecular research, diagnostics, and biomanufacturing. The company operates as a high-margin B2B supplier to global life science and gene therapy companies. Its competitive moat is secured by proprietary enzyme technology, high-barrier manufacturing standards, and strong intellectual property.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	14.1M	12.3M	10.8M	11.6M	-6.3%
EPS	0.07	0.04	0.02	0.02	-33.6%
Shares	50.6M	50.9M	51.1M	51.1M	+1.0%
Debt	1.5M	1.3M	0.8M	0.6M	-27.6%
Equity	29.4M	31.9M	33.5M	34.9M	5.9%
Op CF	6.0M	2.5M	0.2M	2.7M	-23.8%
Inv CF	-3.4M	-2.2M	-1.0M	-0.5M	—
Fin CF	-0.2M	-0.1M	-0.2M	-0.4M	—

PRICE (1Y)+1.5%

SMA 50SMA 200

$2.10

RSI (14)

46.4

52W High

$3.24

From 52W High

0.6%

SCORE BREAKDOWN

Quality

ROIC

3.6%52.6

ROE

4.1%53.4

GP/Assets

33.8%71.2

Op. Margin

-2.1%33.4

FCF/Assets

3.8%65.1

Piotroski

892.7

Int. Cover

44.6x76.0

D/E Ratio

0.06x73.3

Current Ratio

15.83x93.2

Value

P/E (TTM)

78.5x12.6

EV/EBITDA

70.0x7.4

P/FCF

699.1x14.2

P/B

3.1x41.8

P/S

8.1x29.9

Div Yield

—N/A

Momentum

52W High %

65%48.5

RS 6M

-26%58.7

SMA 50/200

0.89x31.5

EPS Rev 4W

-0.2%32.9

EPS Rev 12W

—N/A

EPS Improve

—81.4

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$107M

P/E (Forward)

32.4x

Gross Margin

95.2%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of AZT.OL are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
AZT.OL	ArcticZymes Technologies ASA(you)	$107M	45	HOLD
NYKD.OL	Nykode Therapeutics AS	$109M	46	HOLD
TRMED.OL	Thor Medical ASA	$157M	20	SELL
ZLNA.OL	Zelluna ASA	$51M	20	SELL
CRNA.OL	Circio Holding ASA	$232M	20	SELL
PHO.OL	Photocure ASA	$166M	70	BUY
VISTN.OL	Vistin Pharma ASA	$93M	99	STRONG BUY
MEDI.OL	Medistim ASA	$438M	86	STRONG BUY

Peer medians: ROE 16.1% · P/E 19.0x · Gross margin 93.6%

ArcticZymes Technologies ASA (AZT.OL) — Stock Score Summary

ArcticZymes Technologies ASA (AZT.OL) has a MoatMap StockRank of 45/100 based on Quality (66/100), Value (20/100), and Momentum (50/100) factor scores. The current signal is HOLD. A high-quality Norwegian enzyme producer with strong ROIC potential, serving as a critical upstream supplier to molecular diagnostics and biopharma CDMOs. The asset-light model and high switching costs create a strong moat, though valuation remains demanding.

Key Financial Metrics

Price	$2.10
Market Cap	$107M
P/E (TTM)	78.46
P/E (Forward)	32.43
Price/Book	3.06
Return on Equity	4.1%
Return on Invested Capital	3.6%
Debt/Equity	5.63
Gross Margin	95.2%
Operating Margin	-2.1%
Revenue Growth	40.9%
Free Cash Flow	$153K

ArcticZymes Technologies ASA operates in the Biotechnology industry, part of the Healthcare sector (Norway).

Frequently Asked Questions

What is ArcticZymes Technologies ASA’s (AZT.OL) StockRank?: MoatMap’s StockRank for ArcticZymes Technologies ASA (AZT.OL) is 45/100, with a Hold signal. It is a composite of Quality (66), Value (20), and Momentum (50) factor ranks across MoatMap’s 20,000+ stock universe.
Does ArcticZymes Technologies ASA have an economic moat?: ArcticZymes Technologies ASA (AZT.OL) has a Quality factor score of 66/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is ArcticZymes Technologies ASA a buy, hold, or sell?: MoatMap’s current signal for ArcticZymes Technologies ASA (AZT.OL) is Hold, based on a StockRank of 45/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is ArcticZymes Technologies ASA in?: ArcticZymes Technologies ASA (AZT.OL) operates in the Healthcare sector, specifically the Biotechnology industry (Norway).